Integrum, a Sweden-based manufacturer of bone-anchored prosthetic systems, reported a year-over-year decline in net sales for its fiscal fourth quarter, the company said on Thursday.
The company's operating profit was reduced by SEK 15 million in non-recurring items. Management attributed those one-time charges primarily to the reclassification of inventory to property, plant and equipment, organizational changes and a review of older receivables.
On a reported basis, Integrum registered an EBIT loss of SEK 20 million for the quarter. After adjusting for the non-recurring items, the company's adjusted EBIT loss narrowed to SEK 5 million.
Despite the decline in net sales and the reported losses, Integrum completed a record number of S1 surgeries in the quarter, representing the highest quarterly volume in the company's history. The company also said the underlying cost base had improved, driven by organizational changes and efficiency measures put in place during the period.
Looking ahead to fiscal 2026/27, Integrum said it now operates with a lower cost base that positions the company more favorably. The company plans to keep its commercialization efforts and patient flow initiatives in the United States as a central focus.
Integrum additionally reported increasing activity and growing interest in osseointegration across its priority markets. The company emphasized that the combination of higher procedure volumes and cost reductions are central to its near-term strategy.
Analysis
From a product and commercialization perspective, the quarter presents a mixed picture: procedure volumes reached a historic high, which signals stronger uptake or improved throughput for clinically relevant interventions, while revenue declined and operating profit was impacted by identifiable one-off charges. The reported adjustment from an EBIT loss of SEK 20 million to an adjusted loss of SEK 5 million highlights the material effect of the SEK 15 million in non-recurring items on reported profitability.
Management’s emphasis on a lower cost base and continued focus on U.S. patient flows suggests the company is prioritizing scalability of commercialization and operational efficiency as levers to translate higher procedure volumes into improved financial performance over time.